{"id":"NCT03508700","sponsor":"Tonix Pharmaceuticals, Inc.","briefTitle":"A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD","officialTitle":"A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-19","primaryCompletion":"2019-09-30","completion":"2019-09-30","firstPosted":"2018-04-26","resultsPosted":"2025-02-05","lastUpdate":"2025-02-05"},"enrollment":93,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["PTSD"],"interventions":[{"type":"DRUG","name":"TNX-102 SL 5.6 mg","otherNames":[]}],"arms":[{"label":"TNX-102 SL 5.6 mg","type":"EXPERIMENTAL"}],"summary":"Evaluate the long-term safety of TNX-102 SL 5.6 mg taken daily at bedtime over an additional 40 weeks in patients with PTSD who have participated in a double-blind lead-in study and completed an initial 12-week open-label extension study (TNX-CY-P303).","primaryOutcome":{"measure":"Incidence of Newly Emergent Adverse Events","timeFrame":"40 weeks","effectByArm":[{"arm":"Placebo - TNX-102 SL","deltaMin":26,"sd":null},{"arm":"TNX-102 SL - TNX-102 SL","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":1},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":49},"commonTop":["Hypoaesthesia oral"]}}